Eyenovia Concludes Type A Meeting with FDA Related to MydCombi™ NDA Resubmission

3 years ago

No additional clinical work required; NDA resubmission anticipated in Q3 2022NEW YORK, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc.…

Healx and Ovid Therapeutics to Enter Strategic Partnership

3 years ago

– Ovid to License Gaboxadol to Healx – – Healx to Explore Gaboxadol in Combination Therapies for Fragile X, Other…

Hyperfine Appoints Chip Truwit, M.D. as Senior Medical Director

3 years ago

Creators of the world’s first FDA-cleared portable MRI scales executive team for its next phase of development Dr. Chip Truwit,…

NextCure to Present at 11th Annual SVB Leerink Global Healthcare Conference

3 years ago

BELTSVILLE, Md., Feb. 08, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and…

Beyond Air® Announces Participation at Upcoming Investor Conferences in March 2022

3 years ago

GARDEN CITY, N.Y., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical…

Soleno Therapeutics to Participate in the BIO CEO & Investor Conference

3 years ago

REDWOOD CITY, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing…

Salarius Pharmaceuticals to Participate in the 2022 BIO CEO & Investor Conference

3 years ago

HOUSTON, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines…

Palisade Bio (Nasdaq: PALI) to Announce Adhesions Clinical Data at SAGES 2022 Annual Meeting

3 years ago

Incidence and Severity of Post-Surgical Intraabdominal Adhesions following Bowel Resection Surgery and Treatment with Enteral Protease Inhibitor LB1148CARLSBAD, Calif., Feb.…

Frontier Medicines Announces Renowned Physician Scientist Piro Lito, M.D., Ph.D., Joins Scientific Advisory Board

3 years ago

SOUTH SAN FRANCISCO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock…

GelStat Announces $5 Million Public Offering Under Regulation A+

3 years ago

GelStat Corporation Has Been Qualified by the SEC for a Regulation A+ Public OfferingSTUART, Fla., Feb. 08, 2022 (GLOBE NEWSWIRE)…